Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary A Weiser

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
JAMA|September 24, 2004
The "duty to warn" a patient's family members about hereditary disease risksKenneth Offit, Elizabeth Groeger, Sam Turner, et al.
Cambridge Quarterly of Healthcare Ethics : CQ : the International Journal of Healthcare Ethics Committees|May 27, 2003
The case: can doctors say "enough"?Jeffrey S Groeger, Mary A Weiser, Marguerite S Lederberg, et al.
Cancer|March 20, 2002
Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimenMary A Weiser, Susan O'Brien, Deborah A Thomas, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
JAMA|September 24, 2004
The "duty to warn" a patient's family members about hereditary disease risksKenneth Offit, Elizabeth Groeger, Sam Turner, et al.
Cambridge Quarterly of Healthcare Ethics : CQ : the International Journal of Healthcare Ethics Committees|May 27, 2003
The case: can doctors say "enough"?Jeffrey S Groeger, Mary A Weiser, Marguerite S Lederberg, et al.
Cancer|March 20, 2002
Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimenMary A Weiser, Susan O'Brien, Deborah A Thomas, et al.
Pageof 1